Patent US5567765A successfully refreshed from Google Patents.
US5567765A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods of use
Assignee: Hemagen PFC LP
•
Filing: 1996-02-23
•
Granted: 1996-10-22
•
Expires: 2016-02-23
Abstract
Abstract This invention relates to physiologically acceptable emulsions of perfluorocarbon ether hydrides having 8 to 12 carbon atoms. These novel emulsions have various medical applications. They are especially useful medically as contrast media for various biological imaging modalities such as nuclear magnetic resonance, 19F-magnetic resonance imaging, ultrasound, x-ray, and computed tomography, as oxygen transport agents or "artificial bloods" in the treatment of heart attack, stroke, and other vascular obstructions, as adjuvants to coronary angioplasty and in cancer radiation treatment and chemotherapy.
Inventors
- 👤 George G. I. Moore
- 👤 Richard M. Flynn
- 👤 Miguel A. Guerra
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 23:30
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0026; A61K49/00; A61K49/04; A61K49/0433; A61K49/0447; A61K49/0461; A61K49/06; A61K49/18; A61K49/1806; A61K49/22; A61K49/222; A61K49/226; A61P; A61P35/00; A61P9/00; A61P9/08; A61P9/10; A62; A62D; A62D1/00; A62D1/0028; A62D1/0035; B; B01; B01D; B01D12/00; B23; B23K; B23K35/00; B23K35/22; B23K35/38; B23K35/386; C; C07; C07C; C07C41/00; C07C41/01; C07C41/18; C07C41/24; C07C41/48; C07C43/00; C07C43/02; C07C43/03; C07C43/04; C07C43/12; C07C43/123; C07C43/126; C07C43/18; C07C43/192; C07C43/30; C07C43/313; C07C59/00; C07C59/125; C07C59/135; C07C69/00; C07C69/66; C07C69/67; C07C69/708; C07D; C07D319/00; C07D319/04; C07D319/06; C07C2601/00; C07C2601/12; C07C2601/14; C08; C08J; C08J2203/00; C08J2203/14; C08J2203/146
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
87 words
An artificial blood comprising a physiologically acceptable aqueous emulsion of a saturated C 8 to C 12 perfluorocarbon ether hydride selected from the group consisting of a hydroperfluoroaliphatic ether, a hydroperfluoroaliphatic ether substituted with a perfluoroalicyclic group, and a hydroperfluorocycloaliphatic ether and mixtures thereof, wherein said aliphatic ether has a straight-chain or a branched-chain of carbon atoms, water and a surfactant, wherein the components are contained in the emulsion in amounts for acceptable physioglogical administration, said amounts being therapeutically effective for oxygen transport and delivery in humans.
Claim 2
Dependent Claim
87 words
An artificial blood comprising a physiologically acceptable aqueous emulsion of a saturated C 8 to C 12 perfluorocarbon ether hydride selected from the group consisting of a hydroperfluoroaliphatic ether, a hydroperfluoroaliphatic ether substituted with a perfluoroalicyclic group, and a hydroperfluorocycloaliphatic ether and mixtures thereof, wherein said aliphatic ether has a straight-chain or a branched-chain of carbon atoms, water and a surfactant, wherein the components are contained in the emulsion in amounts for acceptable physioglogical administration, said amounts being therapeutically effective for oxygen transport and delivery in humans.
Claim 3
Dependent Claim
94 words
A composition for minimizing the adverse effects of coronary angioplasty comprising a physiologically acceptable aqueous emulsion of a saturated C 8 to C 12 perfluorocarbon ether hydride selected from the group consisting of a hydroperfluoroaliphatic ether, a hydroperfluoroaliphatic ether substituted with a perfluoroalicyclic group, and a hydroperfluorocycloaliphatic ether and mixtures thereof, wherein said aliphatic ether has a straight-chain or a branched-chain of carbon atoms, water and a surfactant, wherein the components are contained in the emulsion in amounts for acceptable physiogloical administation, said amounts being therapeutically effective for minimizing adverse affects of coronary angioplasty.
Claim 4
Dependent Claim
94 words
A composition for minimizing the adverse effects of coronary angioplasty comprising a physiologically acceptable aqueous emulsion of a saturated C 8 to C 12 perfluorocarbon ether hydride selected from the group consisting of a hydroperfluoroaliphatic ether, a hydroperfluoroaliphatic ether substituted with a perfluoroalicyclic group, and a hydroperfluorocycloaliphatic ether and mixtures thereof, wherein said aliphatic ether has a straight-chain or a branched-chain of carbon atoms, water and a surfactant, wherein the components are contained in the emulsion in amounts for acceptable physiogloical administation, said amounts being therapeutically effective for minimizing adverse affects of coronary angioplasty.
Claim 5
Dependent Claim
98 words
A contrast agent for biological imaging comprising a physiologically acceptable aqueous emulsion of a saturated C 8 to C 12 perfluorocarbon ether hydride selected from the group consisting of a hydroperfluoroaliphatic ether, a hydroperfluoroaliphatic ether substituted with a perfluoroalicyclic group, and a hydroperfluorocycloaliphatic ether and mixtures thereof, wherein said aliphatic ether has a straight-chain or a branched-chain of carbon atoms, water and a surfactant, wherein the components are contained in the emulsion in amounts for accceptable physiogloical administation, said amounts being clinically effective for imaging by nuclear magnetic resonance, 19 F-magnetic resonance imaging, ultrasound, x-ray, and computer tomography.
Claim 6
Dependent Claim
98 words
A contrast agent for biological imaging comprising a physiologically acceptable aqueous emulsion of a saturated C 8 to C 12 perfluorocarbon ether hydride selected from the group consisting of a hydroperfluoroaliphatic ether, a hydroperfluoroaliphatic ether substituted with a perfluoroalicyclic group, and a hydroperfluorocycloaliphatic ether and mixtures thereof, wherein said aliphatic ether has a straight-chain or a branched-chain of carbon atoms, water and a surfactant, wherein the components are contained in the emulsion in amounts for accceptable physiogloical administation, said amounts being clinically effective for imaging by nuclear magnetic resonance, 19 F-magnetic resonance imaging, ultrasound, x-ray, and computer tomography.
Claim 7
Dependent Claim
93 words
A composition for enhancing cancer radiation treatment and chemotherapy comprising a physiologically acceptable aqueous emulsion of a saturated C 8 to C 12 perfluorocarbon ether hydride selected from the group consisting of a hydroperfluoroaliphatic ether, a hydroperfluoroaliphatic ether substituted with a perfluoroalicyclic group, and a hydroperfluorocycloaliphatic ether and mixtures thereof, wherein said aliphatic ether has a straight-chain or a branched-chain of carbon atoms, water and a surfactant, wherein the components are contained in the emulsion in amounts for accceptable physiogloical administation, said amounts being therapeutically effective for enhancing cancer radiation treament and chemotherpy.
Claim 8
Dependent Claim
93 words
A composition for enhancing cancer radiation treatment and chemotherapy comprising a physiologically acceptable aqueous emulsion of a saturated C 8 to C 12 perfluorocarbon ether hydride selected from the group consisting of a hydroperfluoroaliphatic ether, a hydroperfluoroaliphatic ether substituted with a perfluoroalicyclic group, and a hydroperfluorocycloaliphatic ether and mixtures thereof, wherein said aliphatic ether has a straight-chain or a branched-chain of carbon atoms, water and a surfactant, wherein the components are contained in the emulsion in amounts for accceptable physiogloical administation, said amounts being therapeutically effective for enhancing cancer radiation treament and chemotherpy.
Claim 9
Dependent Claim
85 words
A composition for preserving organs comprising a physiologically acceptable aqueous emulsion of a saturated C 8 to C 12 perfluorocarbon ether hydride selected from the group consisting of a hydroperfluoroaliphatic ether, a hydroperfluoroaliphatic ether substituted with a perfluoroalicyclic group, and a hydroperfluorocycloaliphatic ether and mixtures thereof, wherein said aliphatic ether has a straight-chain or a branched-chain of carbon atoms, water and a surfactant, wherein the components are contained in the emulsion in amounts for accceptable physiogloical administation, said amounts being therapeutically effective for preserving organs.
Claim 10
Dependent Claim
85 words
A composition for preserving organs comprising a physiologically acceptable aqueous emulsion of a saturated C 8 to C 12 perfluorocarbon ether hydride selected from the group consisting of a hydroperfluoroaliphatic ether, a hydroperfluoroaliphatic ether substituted with a perfluoroalicyclic group, and a hydroperfluorocycloaliphatic ether and mixtures thereof, wherein said aliphatic ether has a straight-chain or a branched-chain of carbon atoms, water and a surfactant, wherein the components are contained in the emulsion in amounts for accceptable physiogloical administation, said amounts being therapeutically effective for preserving organs.
Claim 11
Dependent Claim
95 words
A composition for treating heart attack, stroke and vascular occlusions comprising a physiologically acceptable aqueous emulsion comprising a saturated C 8 to C 12 perfluorocarbon ether hydride selected from the group consisting of a hydroperfluoroaliphatic ether, a hydroperfluoroaliphatic ether substituted with a perfluoroalicyclic group, and a hydroperfluorocycloaliphatic ether and mixtures thereof, wherein said aliphatic ether has a straight-chain or a branched-chain of carbon atoms, water and a surfactant, wherein the components are contained in the emulsion in amounts for accceptable physiogloical administation, said amounts being therapeutically effective for treating heart attack, stroke and vascular occlusions.
Claim 12
Dependent Claim
95 words
A composition for treating heart attack, stroke and vascular occlusions comprising a physiologically acceptable aqueous emulsion comprising a saturated C 8 to C 12 perfluorocarbon ether hydride selected from the group consisting of a hydroperfluoroaliphatic ether, a hydroperfluoroaliphatic ether substituted with a perfluoroalicyclic group, and a hydroperfluorocycloaliphatic ether and mixtures thereof, wherein said aliphatic ether has a straight-chain or a branched-chain of carbon atoms, water and a surfactant, wherein the components are contained in the emulsion in amounts for accceptable physiogloical administation, said amounts being therapeutically effective for treating heart attack, stroke and vascular occlusions.
Claim 13
Dependent Claim
117 words
The emulsion of any one of claims 1 to 6 wherein said ether is represented by the formula: X--R.sub.f --O(R.sub.f '--O).sub.n R.sub.f "--H wherein: H is a primary hydrogen atom or a 2° hydrogen atom on a carbon adjacent to an ether oxygen atom; X is a fluorine atom or a primary hydrogen atom, or a 2° hydrogen atom on a carbon adjacent to an ether oxygen atom; n is an integer of 0 to 4; and R f , R f ' and R f " are independently selected from unbranched or branched groups consisting of perfluoroalkylene, perfluorocycloalkylene, or perfluorocycloalkylene containing one or more ether oxygens, and which groups may be substituted with an ether oxygen.
Claim 14
Dependent Claim
86 words
The emulsion of any one of claims 1 to 6 wherein said ether is selected from the group consisting of a C 9 -C 10 dihydroperfluorocarbon ether, a C 9 -C 11 perfluorocycloalkyl ether hydride, a C 9 -C 11 perfluorocycloalkyl-substituted perfluoroalkylene ether hydride, a C 9 -C 10 hydroperfluoroalkyl ether where the hydrogen atom is 1° or is 2° bonded to a carbon atom adjacent to an ether oxygen either bonded to an end carbon or intermediate carbon adjacent to an ether, and mixtures thereof.
Claim 15
Dependent Claim
91 words
The emulsion of any one of claims 1 to 6 wherein said ether is selected from the group consisting of H--C.sub.3 F.sub.6 OC.sub.4 F.sub.8 OC.sub.3 F.sub.6 --H, H--C.sub.2 F.sub.4 OCF.sub.2 C(CF.sub.3).sub.2 CF.sub.2 OC.sub.2 F.sub.4 --H, H--C.sub.2 F.sub.4 --O--(CF.sub.2).sub.5 --O--C.sub.2 F.sub.4 --H, H--C.sub.2 F.sub.4 --O--(CF.sub.2).sub.6 --O--C.sub.2 F.sub.4 --H, H--CF.sub.2 O-(C.sub.2 F.sub.4 O).sub.3 CF.sub.2 --H, H--CF.sub.2 O-(C.sub.2 F.sub.4 O).sub.4 CF.sub.2 --H, H--C.sub.2 F.sub.4 --O-cyclo-C.sub.6 F.sub.10 --O--C.sub.2 F.sub.4 --H, cyclo-C.sub.6 F.sub.11 --CF.sub.2 OC.sub.2 F.sub.4 H, cyclo-C.sub.6 F.sub.11 --OC.sub.4 F.sub.8 H, cyclo-C.sub.6 F.sub.11 --C.sub.2 F.sub.4 OCF.sub.2 --H, p-CF.sub.3 O-cyclo-C.sub.6 F.sub.10 --C.sub.2 F.sub.4 --H, ##STR13## ##STR14##
References Cited (Backward Citations)
US3493581A
Cited
US3911138A
Cited
US3911138B1
Cited
US3962439A
Cited
DE2650586A1
Cited
GB1549038A
Cited
US4110474A
Cited
US4187252A
Cited
US4186253A
Cited
US4252827A
Cited
US4443480A
Cited
US4423077A
Cited
US4534978A
Cited
EP0158996A2
Cited
US4686024A
Cited
US4868318A
Cited
US4865836A
Cited
EP0231091A1
Cited
US4866096A
Cited
EP0307087A1
Cited
FR2620445A1
Cited
WO1989010118A1
Cited
WO1992002560A1
Cited
WO1993001798A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-10-22 | 2000-04-22 | 2000-10-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-10-22 | 2004-04-22 | 2004-10-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-10-22 | 2008-04-22 | 2008-10-22 | $7700.00 | Window Closed / Lapsed |